Development of an age-adjusted model for blood neurofilament light chain.

Publisher: Wiley Periodicals, Inc on behalf of American Neurological Association Country of Publication: United States NLM ID: 101623278 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2328-9503 (Electronic) Linking ISSN: 23289503 NLM ISO Abbreviation: Ann Clin Transl Neurol Subsets: MEDLINE

Original Publication: [Hoboken, NJ] : Wiley Periodicals, Inc on behalf of American Neurological Association, [2014]-

Multiple Sclerosis* ; Multiple Sclerosis, Chronic Progressive*; Adult ; Biomarkers ; Humans ; Intermediate Filaments ; Middle Aged ; Neurofilament Proteins ; Recurrence

Objective: To develop an age-adjustment model for neurofilament light chain (NfL), an emerging injury marker in patients with a range of neurologic conditions including multiple sclerosis (MS).
Methods: Serum and plasma samples were collected from a healthy donor (HD) cohort of 118 individuals aged 24 to 66 years, 90 patients with relapsing MS (RMS) and 22 patients with progressive MS (PMS). Serum and plasma samples were assessed for NfL using the SIMOA assay (Quanterix NfL Advantage Kit™). A log-linear model was used to evaluate the relationship between NfL and age and to calculate age-adjusted NfL levels.
Results: Higher serum and plasma NfL levels were significantly associated with increasing HD age. Log-transformation of blood NfL levels reduced heteroscedasticity and skewness. A log-linear model enabled adjustment for age-related increase in serum and plasma NfL levels (2.3% [95% CI, 1.6-2.9] and 2.6% [95% CI, 1.3-3.3] per year, respectively). Following age adjustment, NfL did not show significant association with HD sex or ethnicity. While unadjusted serum NfL levels were elevated in patients with PMS (mean age 56 years) compared with those with RMS (mean age 37 years), age-adjusted NfL levels did not differ.
Interpretation: A log-linear, age adjustment model was developed to enable comparison of NfL levels across populations with different ages. While additional data and evidence are needed for patient-level adoption, this could be a valuable tool for interpreting NfL levels across a range of patient groups with neurologic conditions.
(© 2022 F. Hoffmann-La Roche Ltd. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.)

Nat Rev Dis Primers. 2018 Nov 8;4(1):43. (PMID: 30410033)
Neurology. 2017 Mar 7;88(10):930-937. (PMID: 28179466)
JAMA Neurol. 2019 Mar 1;76(3):264-273. (PMID: 30615028)
Brain. 2018 Aug 1;141(8):2382-2391. (PMID: 29860296)
Lancet Neurol. 2017 Aug;16(8):601-609. (PMID: 28601473)
Neurology. 2019 Mar 5;92(10):e1007-e1015. (PMID: 30737333)
Neurology. 2014 Nov 18;83(21):1945-53. (PMID: 25339208)
J Neuroimaging. 2021 Mar;31(2):388-393. (PMID: 33476489)
JAMA Neurol. 2020 Jan 1;77(1):58-64. (PMID: 31515562)
CNS Neurosci Ther. 2019 Apr;25(4):527-531. (PMID: 30411534)
Scand J Clin Lab Invest. 2020 Jul;80(4):291-295. (PMID: 32077769)
Mol Biol Rep. 2014 Jun;41(6):4017-22. (PMID: 24733614)
Alzheimers Dement (Amst). 2019 Nov 04;11:730-743. (PMID: 31909174)
J Neurovirol. 2018 Dec;24(6):695-701. (PMID: 30105502)
J Neurol Sci. 1994 Apr;122(2):189-203. (PMID: 8021703)
Ann Clin Transl Neurol. 2020 Dec;7(12):2508-2523. (PMID: 33146954)
Nat Commun. 2020 Feb 10;11(1):812. (PMID: 32041951)
JAMA Neurol. 2016 Jan;73(1):60-7. (PMID: 26524180)
Lancet Neurol. 2018 Feb;17(2):162-173. (PMID: 29275977)
Sci Rep. 2016 Nov 07;6:36791. (PMID: 27819296)
Mult Scler. 2020 Apr;26(5):561-567. (PMID: 31965878)
PLoS One. 2019 Apr 5;14(4):e0211575. (PMID: 30951523)
JAMA Neurol. 2019 Sep 1;76(9):1035-1048. (PMID: 31206160)
Alzheimers Res Ther. 2017 Nov 2;9(1):88. (PMID: 29096697)
Endocrine. 2006 Apr;29(2):243-56. (PMID: 16785600)
Neurology. 2014 Jul 15;83(3):278-86. (PMID: 24871874)
Ann Neurol. 2019 Jan;85(1):114-124. (PMID: 30421454)
Sci Rep. 2018 Nov 26;8(1):17368. (PMID: 30478269)
Alzheimers Dement. 2018 Sep;14(9):1171-1183. (PMID: 29907423)
Neurobiol Aging. 2021 Jan;97:10-17. (PMID: 33070094)
Nat Rev Neurol. 2018 Oct;14(10):577-589. (PMID: 30171200)
Neurology. 2020 Jun 9;94(23):e2457-e2467. (PMID: 32434867)
Ann Neurol. 2019 May;85(5):653-666. (PMID: 30851128)
Mult Scler. 2017 Aug;23(9):1258-1267. (PMID: 27738090)
J Neurosurg. 2012 Sep;117(3):629-37. (PMID: 22746378)
Ther Adv Neurol Disord. 2013 Jul;6(4):237-48. (PMID: 23858327)
EBioMedicine. 2015 Nov 22;3:135-140. (PMID: 26870824)
Bioanalysis. 2019 Aug;11(15):1405-1418. (PMID: 31401845)
Neurology. 2008 Apr 1;70(14):1163-70. (PMID: 18003939)
Stroke. 2019 Jul;50(7):1669-1675. (PMID: 31138085)
Ann Neurol. 2017 Jun;81(6):857-870. (PMID: 28512753)
Neurology. 2020 Aug 18;95(7):e827-e838. (PMID: 32680941)

0 (Biomarkers)
0 (Neurofilament Proteins)

Date Created: 20220301 Date Completed: 20220412 Latest Revision: 20220525

20240829

PMC8994974

10.1002/acn3.51524

35229997